R. Kurmasheva

Publications144
h-index24
Citations1,808
Highly Influential Citations62
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Houghton
  • 665 Publications, 26,846 Citations
  • M. Smith
  • 340 Publications, 17,687 Citations
  • R. Lock
  • 327 Publications, 8,197 Citations
  • J. Maris
  • 638 Publications, 29,818 Citations
  • Publications
  • Influence
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Purpose: Inhibitors of PARP, an enzyme involved in base excision repair, have demonstrated single-agent activity against tumors deficient in homologous repair processes. Ewing sarcoma cells are also… Expand
  • 79
  • 7
  • PDF
IGF-I mediated survival pathways in normal and malignant cells.
The type-I and -II insulin-like growth factors (IGF-I, II) are now established as survival- or proliferation-factors in many in vitro systems. Of note IGFs provide trophic support for multiple cell… Expand
  • 174
  • 6
Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
Volasertib (BI 6727) is a potent inhibitor of Polo‐like kinase 1 (Plk1), that is overexpressed in several childhood cancers and cell lines. Because of its novel mechanism of action, volasertib was… Expand
  • 40
  • 5
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2-regulated… Expand
  • 75
  • 4
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program
Quisinostat (JNJ‐26481585) is a second‐generation pyrimidyl‐hydroxamic acid histone deacetylase (HDAC) inhibitor with high cellular potency towards Class I and II HDACs. Quisinostat was selected for… Expand
  • 28
  • 4
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Signaling through the type 1 insulin-like growth factor receptor (IGF-1R) occurs in many human cancers, including childhood sarcomas. As a consequence, targeting the IGF-1R has become a focus for… Expand
  • 138
  • 3
  • PDF
IRS-1: auditing the effectiveness of mTOR inhibitors.
Rapamycin analogs that inhibit mTOR signaling have antitumor activity against certain lymphomas, but treatment of solid tumors has been less encouraging despite inhibition of mTOR function. Two… Expand
  • 70
  • 3
Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2
Previously, we reported that a predominant action of a type-1 insulin-like growth factor receptor (IGF-1R)-targeted antibody was through inhibiting tumor-derived VEGF, and indirectly, angiogenesis.… Expand
  • 55
  • 3
Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia
Purpose: Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage leukemia (MLL) oncogene (infant… Expand
  • 26
  • 3
Predicted mechanisms of resistance to mTOR inhibitors
The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell… Expand
  • 87
  • 2